Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10710 | 0.98 | TDP1 (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14363640 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL546820 | 0.82 | — | — | |
| SCHEMBL14668317 | 0.82 | — | — | |
| Mannitol SCHEMBL11105758 | 0.81 | LMNA (0.57) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL247059 | 0.81 | LMNA (0.57) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL252338 | 0.80 | TDP1 (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL7687990 | 0.79 | TDP1 (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14866617 | 0.79 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL27537130 | 0.79 | TDP1 (0.55) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105792832-A | Organic compounds to treat hepatitis b virus | 诺华股份有限公司 | 2016-07-20 | — | — | CN | claimed |
| CN-105683163-A | 3'end caps for RNAi agents for use in RNA interference | 诺华股份有限公司 | 2016-06-15 | — | — | CN | claimed |
| CN-111050549-B | Controlling viscoelasticity of highly concentrated liquid formulations using EO/PO block copolymer surfactants | 埃科莱布美国股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-111050549-A | Control of viscoelasticity in highly concentrated liquid formulations using EO/PO block copolymer surfactants | 埃科莱布美国股份有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-105683163-B | 3 ' end caps of the RNAi agent used in RNA interference | 诺华股份有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-105792832-A | Organic compounds to treat hepatitis b virus | 诺华股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-105683163-A | 3'end caps for RNAi agents for use in RNA interference | 诺华股份有限公司 | 2016-06-15 | — | — | CN | disclosed |